Results
Data collected included tumor response (at 1, 3, and 6 months), type and intensity grade of adverse events, and quality of life (QOL) analysis.
Quality of Life
- QOL analysis at 1, 3, and 6 months after treatment showed that physical and social functioning were improved for most of the patients.
Tolerability
- There were no complications during the TACE procedure, which was well tolerated by all of the patients
- The most reported AEs of grade 1 or 2 were: fever (33%), elevated liver enzymes (17%), and pain (33%). These AEs resolved without complications.
- No grade 3 or 4 AEs were reported.
Conclusion
These data suggest that PEG embolics are efficacious and safe for the treatment of HCC, as indicated by their good tolerability, QOL scores, and high tumor response.
